Report
EUR 13.98 For Business Accounts Only

NUVASIVE sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of NUVASIVE (US), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 2 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 31, 2021, the closing price was USD 52.48 and its potential was estimated at USD 60.09.
Underlying
NuVasive Inc.

Nuvasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for spine surgery. The company's principal product offering includes a minimally disruptive surgical platform, Maximum Access Surgery. The platform includes the company's proprietary software-driven nerve detection and avoidance systems, and Intraoperative Monitoring services and support; MaXcess, an integrated split-blade retractor system; and implants and biologics. The company's spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are used to enable surgeon access to the spine to perform restorative and fusion procedures.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch